Senzime Secures New Contract With Leading US Healthcare System
Senzime AB (STO:SEZI)(OTCQX:SNZZF) has secured an initial purchasing contract with a hospital of a top 5 US-based Integrated Delivery Network (IDN) on the US East Coast. The contract includes the installation and use of Senzime's TetraGraph neuromuscular system in all operating rooms, following a comprehensive clinical and competitive evaluation.
CEO Philip Siberg highlighted this as a strategic win, demonstrating Senzime's position as a leader in the rapidly transitioning US market for EMG-based neuromuscular monitoring. The contract opens doors to one of the top 5 leading IDNs in the US, with an addressable market potential of over 100,000 patients annually.
TetraGraph is a quantitative train-of-four monitoring system used by anesthesiologists worldwide, meeting recent US and European guidelines for monitoring patients receiving paralytic drugs. It aids in determining correct dosages and post-surgery recovery.
Senzime AB (STO:SEZI)(OTCQX:SNZZF) ha concluso un contratto iniziale di acquisto con un ospedale di una top 5 Integrated Delivery Network (IDN) con sede negli Stati Uniti sulla costa est degli Stati Uniti. Il contratto include l'installazione e l'uso del systema neuromuscolare TetraGraph di Senzime in tutte le sale operatorie, a seguito di una valutazione clinica e competitiva approfondita.
Il CEO Philip Siberg ha sottolineato questo come un successo strategico, dimostrando la posizione di Senzime come leader nel mercato statunitense in rapida transizione per il monitoraggio neuromuscolare basato su EMG. Il contratto apre le porte a una delle prime 5 IDN negli Stati Uniti, con un potenziale di mercato indirizzabile di oltre 100.000 pazienti all'anno.
TetraGraph è un sistema di monitoraggio quantitativo del train-of-four utilizzato dagli anestesisti in tutto il mondo, che soddisfa le recenti linee guida statunitensi ed europee per il monitoraggio dei pazienti che ricevono farmaci paralizzanti. Aiuta a determinare le dosi corrette e il recupero post-operatorio.
Senzime AB (STO:SEZI)(OTCQX:SNZZF) ha asegurado un contrato inicial de compra con un hospital de una de las 5 principales Redes de Entrega Integradas (IDN) con sede en EE.UU. en la costa este de EE.UU. El contrato incluye la instalación y el uso del sistema neuromuscular TetraGraph de Senzime en todas las salas de operaciones, tras una evaluación clínica y competitiva exhaustiva.
El CEO Philip Siberg destacó esto como una victoria estratégica, demostrando la posición de Senzime como líder en el mercado estadounidense que está en rápida transición hacia el monitoreo neuromuscular basado en EMG. El contrato abre las puertas a una de las 5 IDN principales en EE.UU., con un potencial de mercado accesible de más de 100,000 pacientes anuales.
TetraGraph es un sistema de monitoreo cuantitativo del train-of-four utilizado por anestesiólogos en todo el mundo, cumpliendo con las recientes pautas de EE.UU. y Europa para el monitoreo de pacientes que reciben medicamentos paralizantes. Ayuda a determinar las dosis correctas y la recuperación post-operatoria.
Senzime AB (STO:SEZI)(OTCQX:SNZZF)는 미국 동부에 있는 미국 내 5대 통합 전달 네트워크(IDN)의 병원과 초기 구매 계약을 체결했습니다. 이 계약은 종합적인 클리니컬 및 경쟁 평가를 거쳐 모든 수술실에서 Senzime의 TetraGraph 신경근 모니터링 시스템의 설치 및 사용을 포함합니다.
CEO 필립 시베르크는 이것을 전략적 승리로 강조하며, EMG 기반 신경근 모니터링을 위한 빠르게 변화하는 미국 시장에서 Senzime의 위치를 보여줍니다. 이 계약은 미국에서 가장 저명한 5대 IDN 중 하나에 대한 접근을 열어주며, 연간 100,000명 이상의 환자를 위한 시장 잠재력이 있습니다.
TetraGraph는 전 세계 마취과 의사들이 사용하는 정량적 train-of-four 모니터링 시스템으로, 마비약을 받는 환자 모니터링을 위한 최근 미국 및 유럽 가이드라인을 충족합니다. 정확한 투여량 및 수술 후 회복을 결정하는 데 도움을 줍니다.
Senzime AB (STO:SEZI)(OTCQX:SNZZF) a sécurisé un contrat d'achat initial avec un hôpital d'un top 5 des réseaux de soins intégrés (IDN) basé aux États-Unis sur la côte est des États-Unis. Le contrat inclut l'installation et l'utilisation du système neuromusculaire TetraGraph de Senzime dans toutes les salles d'opération, suite à une évaluation clinique et concurrentielle approfondie.
Le CEO Philip Siberg a souligné cela comme une victoire stratégique, démontrant la position de Senzime en tant que leader sur le marché américain en pleine transition pour le monitoring neuromusculaire basé sur l'EMG. Le contrat ouvre des portes à l'un des 5 principaux IDN aux États-Unis, avec un potentiel de marché adressable de plus de 100 000 patients par an.
TetraGraph est un système de surveillance quantitative train-of-four utilisé par des anesthésistes du monde entier, répondant aux récentes directives américaines et européennes pour le suivi des patients recevant des médicaments paralysants. Il aide à déterminer les doses correctes et la récupération post-chirurgicale.
Senzime AB (STO:SEZI)(OTCQX:SNZZF) hat einen ersten Kaufvertrag mit einem Krankenhaus eines der 5 größten integrierten Gesundheitsnetzwerke (IDN) in den USA an der US-Ostküste gesichert. Der Vertrag umfasst die Installation und Nutzung des TetraGraph-Neuromuskulären Systems von Senzime in allen OP-Räumen, nach einer umfassenden klinischen und wettbewerbsfähigen Bewertung.
CEO Philip Siberg hob dies als strategischen Erfolg hervor, der Senzimes Stellung als führendes Unternehmen im sich schnell verändernden US-Markt für EMG-basiertes neuromuskuläres Monitoring demonstriert. Der Vertrag öffnet Türen zu einem der 5 führenden IDNs in den USA, mit einem adressierbaren Marktpotential von über 100.000 Patienten jährlich.
TetraGraph ist ein quantitatives Train-of-Four-Monitoringsystem, das von Anästhesisten weltweit verwendet wird und die neuesten US-amerikanischen und europäischen Richtlinien für die Überwachung von Patienten, die Lähmungsmittel erhalten, erfüllt. Es hilft dabei, die richtigen Dosierungen und die Genesung nach der Operation zu bestimmen.
- Secured contract with a top 5 US-based Integrated Delivery Network hospital
- TetraGraph system to be installed in all operating rooms of the contracted hospital
- Addressable market potential of over 100,000 patients annually within the IDN
- Demonstrates Senzime's leadership in the rapidly transitioning US market for EMG-based neuromuscular monitoring
- TetraGraph meets recent US and European guidelines for monitoring patients receiving paralytic drugs
- None.
UPPSALA, SWEDEN / ACCESSWIRE / September 24, 2024 / Senzime AB (STO:SEZI)(OTCQX:SNZZF) today announced that it has secured an initial purchasing contract with a hospital of a top 5 US-based Integrated Delivery Network (IDN) with strong presence on the US East Coast. The contract includes install and use of Senzime's TetraGraph neuromuscular system in all its operating rooms, and was awarded following a comprehensive clinical and competitive evaluation.
"This is yet another strategic win for us on the US market. We continue to demonstrate that we have the neuromuscular monitoring solutions of choice, the know-how and the support that hospitals demand to meet the new clinical guidelines. The transition to EMG-based neuromuscular monitoring continues in a rapid pace in the US market and Senzime continues to lead this shift. This new contract represents a strategic door opening into one of the top 5 leading IDN's in the US, with an addressable market potential of over 100,000 patients a year", comments Philip Siberg, CEO of Senzime.
Senzime's TetraGraph is a state-of-the-art quantitative train-of-four monitoring system used by anesthesiologists at hundreds of leading hospitals worldwide. Its proprietary technology meets the requirements of the recently published US and European recommending monitoring of all patients receiving paralytic drugs. The TetraGraph helps anesthesiologists accurately determine the correct dose of paralytic drugs and their antagonists and determines when patients have safely recovered post-surgery.
For further information, please contact:
Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com
About Senzime
Senzime, headquartered in Sweden, is a leading medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. The company provides an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for accurate monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.
Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world's leading markets. The company's shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at senzime.com.
Attachments
Senzime secures new contract with leading US healthcare system
SOURCE: Senzime
View the original press release on accesswire.com
FAQ
What new contract has Senzime (SNZZF) secured in September 2024?
How many potential patients could Senzime (SNZZF) reach annually with this new contract?
What is the TetraGraph system by Senzime (SNZZF) used for?
How does Senzime's (SNZZF) TetraGraph system align with recent medical guidelines?
